Companies
Oobli
describes itself as the first and only commercial-scale sweet-protein technology platform; received its third FDA "no questions" letter in September 2025 for its brazzein-based sweetening ingredient, and announced an Andean regional manufacturing partnership in April 2026 with Magdalena,…
- Country
- United States
Coverage
| EU | US | |
|---|---|---|
| food-alt-protein | ✓ | ✓ |
Regulatorsfdaefsa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Approximately $43M - $50M in total funding raised to date | oobli.com · caplight.com |
| Production site | Research lab in Davis, California; manufacturing conducted at a contract facility in Los Angeles, California | wyomingnews.com |
| Certification | Three FDA GRAS 'no questions' letters; multiple proteins with self-affirmed FDA GRAS status; one protein with FEMA GRAS status | oobli.com |
| Regulatory approval | Three FDA 'no questions' letters received (as of September 2025) | oobli.com · prnewswire.com · proteinproductiontechnology.com |
| Headcount | Approximately 42-45 employees medium confidence | bouncewatch.com · prospeo.io · datanyze.com |
| Revenue | Estimated between $3.8M and $39.7M annually medium confidence | prospeo.io · datanyze.com |
Independent sources: bouncewatch.com · caplight.com · datanyze.com · prnewswire.com · prospeo.io · proteinproductiontechnology.com · wyomingnews.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Sweet proteins (brazzein, thaumatin, monellin) | food-alt-protein | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.